Nantahala Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Nantahala Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-750,000	Closed	-$25.1M	–	172
2026 Q1	$25.1M	Buy	750,000 +248,000	+49%	+$9.72M	0.92%	26
2025 Q4	$23.2M	Buy	502,000 +402,000	+402%	+$22M	0.77%	29
2025 Q3	$6.76M	Buy	+100,000	New	+$7.41M	0.23%	93

Nantahala Capital Management's SLNO Position: Q2 2026 in Review

Nantahala Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,744,124 shares — an estimated $58.4M sold.

Nantahala Capital Management first reported a position in SLNO in Q4 2019 and held it in 26 quarters. The position peaked at $177M in Q4 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Nantahala Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Nantahala Capital Management sold 1,744,124 Soleno Therapeutics shares in Q2 2026, an estimated $58.4M.
Nantahala Capital Management first reported a position in Soleno Therapeutics in Q4 2019 and held it in 26 quarters.
Nantahala Capital Management's Soleno Therapeutics position peaked at $177M in Q4 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.